Thompson Davis & CO. Inc. Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Thompson Davis & CO. Inc. reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 43.8% in the third quarter, HoldingsChannel.com reports. The firm owned 3,530 shares of the company’s stock after selling 2,750 shares during the period. Thompson Davis & CO. Inc.’s holdings in Novo Nordisk A/S were worth $420,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the period. DSM Capital Partners LLC lifted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new stake in Novo Nordisk A/S in the third quarter valued at $98,765,000. Price T Rowe Associates Inc. MD increased its position in Novo Nordisk A/S by 10.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock valued at $1,102,857,000 after purchasing an additional 823,036 shares during the period. Finally, Marshall Wace LLP raised its holdings in Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $102.65 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The firm’s 50-day simple moving average is $117.40 and its two-hundred day simple moving average is $129.27. The stock has a market cap of $460.62 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NVO. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.